TS03 Inc Trust Units TSTIF

RE:RE:RE:RE:Anybody

[echo2]

This approval includes complex scopes, including duodenoscopes, gastroscopes, and colonoscopes,  as outlined in the press release. FDA did not want to specifically name the scopes and will leave IFU’s to TSO3 (testing already done for the important scopes such as the Q180V duodenoscope by Olympus implicated in so many infections and problems) and to the OEM’s. I do not believe Olympus has cooperated with either the FDA or with TSO3 to do an IFU and I expect their lawyers continue to advise them to deny any liability or responsibility for associated infections that would occur if they were to publicly admit to a problem and point to the TSO3 remedy. Other lawyers might have another interest, however, such as mitigating damages and preventing further injuries. FDA is now forcing OEM’s to do post-market evaluations of contaminated scopes. How long will it take for users and hospitals and their lawyers to wake up to the fact that there is now a definitive solution? Not long, once TSO3 has detailed them on this clearly differentiating advantage if the VP4! When will the general media, including Chad Terhune, get this news into the LATimes and other outlets who have taken an interest in this important public health issue? As has been mentioned before, it would not be a surprise to see Olympus just buy TSO3 for $3-4/share and put an end to their own misery. TSO3 will be giving this groundbreaking info to anyone who is interested. As of tomorrow! Again, this share price is ludicrous! I hope Ninepoint has finally dumped the last of their position so this company can be valued for many multiples of where it is today!